Cargando…

Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation

Bacterial conjunctivitis significantly impacts public health, including more than one-third of eye diseases reported worldwide. It is an infection caused by various aerobic and anaerobic bacteria and is highly contagious. Therefore, it has a high incidence of bacterial resistance to the antibiotics...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jesus, José Izo Santana da Silva, Lourenço, Felipe Rebello, Ishida, Kelly, Barreto, Thayná Lopes, Avino, Valdir Carlos, Neto, Edson dos Santos, Bou-Chacra, Nádia Araci
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609799/ https://www.ncbi.nlm.nih.gov/pubmed/36297656 http://dx.doi.org/10.3390/pharmaceutics14102221

Ejemplares similares

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
por: Khimdas, S., et al.
Publicado: (2011)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
por: Haas, Wolfgang, et al.
Publicado: (2013)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen, Steven A, et al.
Publicado: (2013)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach
por: Al Hagbani, Turki, et al.
Publicado: (2023)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Comstock, Timothy L, et al.
Publicado: (2010)

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
por: Mah, Francis S., et al.
Publicado: (2016)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
por: Haas, Wolfgang, et al.
Publicado: (2010)

Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
por: dos Santos, Giselly Almeida, et al.
Publicado: (2020)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra, Ranjan, et al.
Publicado: (2012)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Torkildsen, Gail, et al.
Publicado: (2010)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

Development and Validation of Different Ultraviolet-Spectrophotometric Methods for the Estimation of Besifloxacin in Different Simulated Body Fluids
por: Singh, C. L., et al.
Publicado: (2015)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2015)

Evaluation of the DDSolver Software Applications
por: Zuo, Jieyu, et al.
Publicado: (2014)

Commentary: Dawn of smartphones in frugal ophthalmic innovation
por: Akkara, John Davis
Publicado: (2018)

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes
por: Schechter, Barry A., et al.
Publicado: (2019)

Osteo-odonto keratoprosthesis: Innovative dental and ophthalmic blending
por: Kaur, Jaswinder
Publicado: (2018)

Instillation of Ophthalmic Formulation Containing Nilvadipine Nanocrystals Attenuates Lens Opacification in Shumiya Cataract Rats
por: Goto, Ryoka, et al.
Publicado: (2021)

Antiulcerogenic Potential Activity of Free and Nanoencapsulated Passiflora serratodigitata L. Extracts
por: Strasser, Marc, et al.
Publicado: (2014)

An innovative strategy for standardized, structured, and interoperable results in ophthalmic examinations
por: Mun, Yongseok, et al.
Publicado: (2021)

Commentary: Call for innovative indigenous ideas in smartphone ophthalmic imaging
por: Pujari, Amar, et al.
Publicado: (2020)

The Development and Clinical Application of Innovative Optical Ophthalmic Imaging Techniques
por: Alexopoulos, Palaiologos, et al.
Publicado: (2022)

Crystallization and Growth of Colloidal Nanocrystals
por: Leite, Edson Roberto, et al.
Publicado: (2012)

Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy
por: El-Gendy, Mohamed A., et al.
Publicado: (2023)

Calcium-doped zinc oxide nanocrystals as an innovative intracanal medicament: a pilot study
por: de Souza, Gabriela Leite, et al.
Publicado: (2022)

Editorial: The development and clinical application of innovative optical ophthalmic imaging techniques
por: Zhang, Jinze, et al.
Publicado: (2022)

Application of iontophoresis in ophthalmic practice: an innovative strategy to deliver drugs into the eye
por: Wei, Dong, et al.
Publicado: (2023)

Development of a Novel In Vitro Model to Study Lymphatic Uptake of Drugs via Artificial Chylomicrons
por: Yousef, Malaz, et al.
Publicado: (2023)

Outcome of corneal transplantation in a private institution in Saudi Arabia
por: Omar, Nazri, et al.
Publicado: (2013)

Innovations in glaucoma surgery from Dr. Rajendra Prasad Centre for Ophthalmic Sciences
por: Dada, Tanuj, et al.
Publicado: (2017)

Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases
por: Monteiro, Lis Marie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1sbfr93qu9jg3geds08c9hft0q